Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Pediatr Transplant ; 24(1): e13594, 2020 02.
Article in English | MEDLINE | ID: mdl-31680369

ABSTRACT

Both acute GVHD and chronic GVHD remain the leading cause of morbidity and death after allogeneic HSCT. We conducted a retrospective analysis comparing two GVHD-prophylaxis regimens: 35 patients received "Regimen 1" (horse ATG, tacrolimus, and methotrexate) and 46 "Regimen 2" (rabbit ATG, rituximab, and peritransplant bortezomib). All 81 patients with a median age of 9 (0.6-23) years with ALL (n = 31) or AML (n = 50) in complete remission received TCRαß/CD19-depleted transplants between May 2012 and October 2016, from 40 HLA-matched unrelated and 41 haploidentical donors. After a median follow-up of 3.9 years, the CI of acute GVHD II-IV was 15% (95% CI: 7-30) in the "Regimen 2" group and 34% (95% CI: -54) in the "Regimen 1" group, P = .05. "Regimen 2" was also more effective in the prevention of chronic GVHD; the CI at 1 year after HSCT was 7% (95% CI: 2-19) vs 31% (95% CI: 19-51), P = .005. The CI of relapse at 3 years adjusted for the GVHD-prophylaxis regimen groups 31% (95% CI: 19-51) for the "Regimen 1" vs 21% (95% CI: 11-37) for the "Regimen 2", P = .3. The retrospective observation suggests that the use of the rATG, rituximab, and bortezomib was associated with significantly lower rate of GVHD without the loss of anti-leukemic activity.


Subject(s)
Antilymphocyte Serum/therapeutic use , Bortezomib/therapeutic use , Graft vs Host Disease/prevention & control , Hematopoietic Stem Cell Transplantation , Immunosuppressive Agents/therapeutic use , Leukemia/therapy , Rituximab/therapeutic use , Adolescent , Antigens, CD19 , Child , Child, Preschool , Drug Therapy, Combination , Female , Follow-Up Studies , Hematopoietic Stem Cell Transplantation/methods , Humans , Infant , Leukemia/immunology , Male , Receptors, Antigen, T-Cell, alpha-beta , Retrospective Studies , Treatment Outcome , Young Adult
2.
Cell Cycle ; 11(22): 4222-41, 2012 Nov 15.
Article in English | MEDLINE | ID: mdl-23095639

ABSTRACT

There is a relationship between various cellular stress factors and aging. In earlier studies, we demonstrated that overexpression of the D-GADD45 gene increases the life span of Drosophila melanogaster. In this study, we investigate the relationship between D-GADD45 activity and resistance to oxidative, genotoxic and thermal stresses as well as starvation. In most cases, flies with constitutive and conditional D-GADD45 overexpression in the nervous system were more stress-resistant than ones without overexpression. At the same time, most of the studied stress factors increased D-GADD45 expression in the wild-type strain. The lifespan-extending effect of D-GADD45 overexpression was also retained after exposure to chronic and acute gamma-irradiation, with doses of 40 сGy and 30 Gy, respectively. However, knocking out D-GADD45 resulted in a significant reduction in lifespan, lack of radiation hormesis and radioadaptive response. A dramatic decrease in the spontaneous level of D-GADD45 expression was observed in the nervous system as age progressed, which may be one of the causes of the age-related deterioration of organismal stress resistance. Thus, D-GADD45 expression is activated by most of the studied stress factors, and D-GADD45 overexpression resulted in an increase of stress resistance.


Subject(s)
Drosophila Proteins/metabolism , Gamma Rays , Herbicides/toxicity , Intracellular Signaling Peptides and Proteins/metabolism , Oxidative Stress/drug effects , Animals , Drosophila Proteins/genetics , Drosophila melanogaster/metabolism , Drug Resistance , Female , Genotype , Hormesis , Intracellular Signaling Peptides and Proteins/genetics , Longevity , Male , Mutation , Nervous System/metabolism , Paraquat/toxicity , Starvation , Temperature , GADD45 Proteins
SELECTION OF CITATIONS
SEARCH DETAIL